Pressmeddelanden

17 december, 2022 10:28

COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) EXTRAORDINARY GENERAL MEETING 16 DECEMBER 2022

Läs mer

25 november, 2022 10:45

NOTICE OF EXTRAORDINARY GENERAL MEETING IN ICOAT MEDICAL AB (PUBL)

Läs mer

15 november, 2022 08:00

iCoat Medical publishes Interim Report Q3 2022

Läs mer

19 oktober, 2022 17:00

The U.S. Food and Drug Administration has granted iCoat Medical Orphan Drug Designation for TUM012 in the United States

Läs mer

11 oktober, 2022 13:00

ICOAT MEDICAL ANNOUNCES SECOND INTERIMDATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012

Läs mer

25 augusti, 2022

iCoat Medical publishes Interim Report Q2 2022

Läs mer

10 augusti, 2022

ICOAT MEDICAL ANNOUNCES INTERIM DATA FROM ONGOING FIRST-IN-HUMAN TRIAL WITH NOVEL DRUG TUM012

Läs mer

16 juni, 2022

COMMUNIQUÉ FROM ICOAT MEDICAL AB’S (PUBL) ANNUAL GENERAL MEETING 15 JUNE 2022

Läs mer

13 juni, 2022

iCoat Medical to present at the 14th International Conference on Complement Therapeutics in Rhodes, Greece in June 2022

Läs mer

4 juni, 2022

iCoat Medical to present at the 29th International Congress of The Transplantation Society in Buenos Aires, Argentina in September 2022

Läs mer

20 maj, 2022

NOTICE OF ANNUAL GENERAL MEETING IN ICOAT MEDICAL AB (PUBL)

Läs mer

16 maj, 2022

iCoat Medical publishes Annual Report 2021

Läs mer

9 maj, 2022

Göran Lerenius joins iCoat Medical as General Counsel

Läs mer

25 april, 2022

iCoat Medical’s Chief Medical Officer Alireza Biglarnia featured in article from Njurfonden

Läs mer

21 april, 2022

The European Commission has granted iCoat Medical Orphan Drug Designation for TUM012 in the EU

Läs mer

25 mars, 2022

Jacob Westman joins iCoat Medical as Head of CMC

Läs mer

11 januari, 2022

Mattias Springare joins iCoat Medical as CFO and Head of Investor Relations

Läs mer